جست‌وجوی استاد و پژوهشگر

Philippe Gallayمشاهده پروفایل

استاد

• Virology
• Immunology
• Antiviral Therapeutics
• +۳ مورد دیگر

Philippe Gallay, PhD, is a Professor of Immunology in the Department of Immunology and Microbial Science at The Scripps Research Institute. His research focuses on the interplay between host factors and viruses, particularly HIV and HCV, aiming to develop novel antiviral therapies. He holds a PhD in Bacteriology/Immunology from the University of Lausanne (1993) and has held academic positions since 1997, including roles as Professor and Associate Professor. Key research interests include HIV latency reversal, HBV cure strategies using AAV vectors, and SARS-CoV-2 therapies targeting viral entry mechanisms. His lab has pioneered cyclophilin inhibitors (e.g., CRV431) for HCV and HIV, and developed nasal sprays to combat SARS-CoV-2 variants. Notable publications span antiviral drug combinations, viral replication mechanisms, and translational models in humanized mice. Awards: 1994 AIDS Award (Bristol-Myers Squibb), Prix Brunner Thesis Award (University of Lausanne). Grants/Labs: Collaborations on HBV cure strategies using AAV vectors, HIV latency reversal via IAP antagonists, and SARS-CoV-2 antivirals like astodrimer sodium. His work spans virology, pharmacology, and translational medicine, with a focus on high-impact human health threats like HIV, HCV, and emerging viruses.

• Microbial Genomics
• Public Health
• Antimicrobial Resistance
• +۱۲ مورد دیگر

Alexandra Isabel Cardoso Nunes is a researcher at the Genomics and Bioinformatics Unit of the Department of Infectious Diseases at the Portuguese National Institute of Health (INSA), and an invited professor at the Faculty of Veterinary Medicine and the School of Psychology and Life Sciences at Lusófona University (ULusófona). She is actively involved in national and international research projects under the One Health framework, particularly in antimicrobial resistance, pathogen genomics, and outbreak surveillance. Her research interests span Microbial Genomics, Public Health, Antimicrobial Resistance (AMR), Bioinformatics, Pathogen Evolution, and One Health . She employs advanced genomic and transcriptomic techniques to study bacterial and viral pathogens, with a focus on Chlamydia trachomatis , Salmonella , Campylobacter , Mycobacterium tuberculosis , and SARS-CoV-2 . Her work integrates laboratory and computational methods for integrative surveillance and drug development. Her recent publications highlight trends in zoonotic pathogen transmission, AMR in food-producing animals, genomic surveillance of emerging outbreaks (e.g., mpox, SARS-CoV-2), and development of novel antimicrobial materials . These studies are increasingly interdisciplinary, combining veterinary, human, and environmental health perspectives under the One Health umbrella. European ERA-NET PathoGenoMics Ph.D. Award 2011 Gold Medal for Distinguished Services from the Portuguese Ministry of Health ASA Travel Award 2014 Nunes has (co-)supervised 27 students, including postdoctoral researchers, PhD, MSc, and BSc candidates, and currently mentors 10 students. She has participated in over 30 national and international research projects, including EU4Health, Horizon 2020, and ECDC-funded initiatives. She is a member of COST Action CA21145 'EURESTOP' and the Animal and Veterinary Research Centre (CECAV). She leads the development of bioinformatics tools like INSaFLU-TELEVIR for viral genomic surveillance and is co-inventor of a European patent on surfactant-based hydrogels for infection prevention. Her work bridges research, public health policy, and technological innovation.

• HIV Research
• Virology
• Molecular Biology
• +۵ مورد دیگر

Professor Susana Valente serves as Professor and Chair of the Department of Immunology and Microbiology at UF Scripps Biomedical Research (University of Florida), with concurrent appointments at The Scripps Research Institute and The Wertheim UF Scripps Institute. Her research program focuses on molecular mechanisms of HIV replication and latency, particularly host-virus interactions governing viral transcription. Valente earned her Ph.D. in Microbiology-Virology from the University of Paris Diderot (2002), preceded by Master's degrees in Biotechnology (De Montfort University, 1998) and Biochemistry (University of Paris Diderot, 1997), following undergraduate studies at New University of Lisbon. Her postdoctoral training occurred at Columbia University. Her research centers on host cellular factors regulating HIV transcription, with pioneering work on the "block-and-lock" HIV cure strategy using didehydro-cortistatin A (dCA). Key investigations include: Chromatin remodeling complexes in HIV latency Tat protein interactions with host transcription machinery Epigenetic control of viral reservoirs Development of small molecule inhibitors targeting transcriptional regulators Impact of comorbidities on HIV persistence Analysis of her 15 most recent publications reveals sustained focus on transcriptional control mechanisms, particularly host chromatin remodelers (p400 complex, p32) and transcription factors (PU.1, FUBP3). Her work demonstrates how epigenetic modifications maintain viral latency and how compounds like dCA induce deep latency, advancing the "block-and-lock" paradigm for functional HIV cure. Valente's scientific recognition includes: NIAID MERIT Award (2022) Landenberger Foundation early-career awards (2009-2012) amfAR Fellowship (1998-2002) NIH-NIAID Career Transition Award (2007-2008) Portuguese Ministry of Education Fellowships She currently leads 12 active grants totaling over $15M, including NIAID R01 awards for HIV transcription disruption (2025), brain organoid development for neuroHIV studies (2024), and HOPE Collaboratory leadership (2022). Her NIH funding history spans 20+ years, with recent expansion into SARS-CoV-2 research. Valente serves on editorial boards for Viruses and Retrovirology, and previously on NIH study sections (2014-2020). The Valente Lab employs multidisciplinary approaches combining molecular virology, epigenetics, and cell biology to investigate HIV persistence mechanisms. Current projects include developing brain organoids to model HIV-associated cognitive impairment and testing novel Tat inhibitors in humanized mouse models, with extensive collaborations across the HIV cure research network.

Nesha Haniffمشاهده پروفایل

مدرس

• Empowerment Pedagogies
• HIV/AIDS Education
• Gender Studies
• +۹ مورد دیگر

Nesha Z. Haniff is a Lecturer at the University of Michigan, affiliated with the Women's and Gender Studies and Afroamerican and African Studies departments. She previously served as faculty at the Center for Latin American and Caribbean Studies and the African Studies Center. Ph.D. in Social Foundations of Education (1984) from University of Michigan Her research focuses on empowerment pedagogies addressing marginalized populations, particularly through HIV/AIDS education, gender justice, and LGBTQ+ activism across the Caribbean, South Africa, and the United States. She pioneered innovative educational modules on: HIV/AIDS prevention and community education Women's reproductive health and agency Combating homophobia in Black communities Developing microbicides for women's sexual safety She emphasizes praxis-based learning where students become activists through transnational engagement with these issues.

Elizabeth Brownمشاهده پروفایل

استاد پژوهشی

• Biostatistics
• Clinical Trials
• HIV/AIDS Research
• +۷ مورد دیگر

Dr. Elizabeth Brown holds dual roles as a Research Professor in Biostatistics at the University of Washington School of Public Health and a Professor in the Biostatistics, Bioinformatics, and Epidemiology Program at Fred Hutchinson Cancer Center. She leads the Statistical and Data Management Center of the Microbicide Trials Network and directs the Statistical and Data Sciences Unit for the Infectious Diseases Clinical Research Consortium. Her work focuses on designing and analyzing clinical trials for HIV/AIDS, HPV, and COVID-19 prevention. Education: ScD (Biostatistics, Harvard University, 2002), MS (Biometrics, University of Colorado, 1998), BS (Mechanical Engineering, University of Virginia, 1994) Key Appointments: Member of the Translational Data Science Integrated Research Center at Fred Hutch, Principal Investigator for the Microbicide Trials Network. Research interests include joint longitudinal-spatial models for infectious diseases, causal inference in clinical trials, and Bayesian methods for survival analysis. Her projects span HIV prevention (e.g., dapivirine vaginal ring), cardiovascular outcomes, and global vaccine trials. She has contributed to major milestones such as the European Medicines Agency approval of HIV prevention interventions.

Johanna B. Holmمشاهده پروفایل

استادیار

• Vaginal Microbiome
• Women's Reproductive Health
• Sexually Transmitted Infections
• +۴ مورد دیگر

Johanna B. Holm is an Assistant Professor in the Department of Microbiology and Immunology at the University of Maryland School of Medicine, where she also holds appointments as a Member of the Institute for Genome Sciences and the Center for Advanced Microbiome Research and Innovation. Her laboratory integrates computational and experimental approaches to investigate the vaginal microbiome's role in women's reproductive health, with a focus on bacterial vaginosis (BV) and sexually transmitted infections (STIs). Her educational journey began with undergraduate research at Millersville University of Pennsylvania in Dr. Jean Boal's cephalopod laboratory, where she studied learning and communication in marine invertebrates. She earned her Ph.D. in Marine and Environmental Biology from the University of Southern California under Dr. Karla Heidelberg, conducting foundational work on coral-associated microbiomes and hypersaline lake ecology. Her postdoctoral training occurred in the laboratories of Dr. Rebecca Brotman and Dr. Jacques Ravel at the University of Maryland School of Medicine. Dr. Holm's research centers on defining microbial and molecular mechanisms by which cervicovaginal microbiota modulate host susceptibility to pathogens like Chlamydia trachomatis and Trichomonas vaginalis . Her lab develops bioinformatic tools for high-resolution microbiome analysis and employs 3D organotypic models to validate hypotheses. A key objective is replacing symptom-based diagnostics with metagenomic community state types (mgCSTs) that predict infection risk and BV recurrence, aiming to develop antibiotic-sparing interventions. Analysis of her recent publications reveals a strong emphasis on vaginal microbiome characterization through multi-omics integration, with consistent themes including pathogen-microbiome interactions, computational tool development (e.g., VALENCIA classifier), and translational applications for women's health. Her work spans methodological advances in low-biomass sample analysis, cross-population studies of microbiome-disease associations, and mechanistic investigations of host responses. Her scientific achievements have been recognized through: NIAID F32 Postdoctoral Fellowship (AI136400) NIAID K01 Career Development Award (AI163413) Dr. Holm actively mentors trainees in both bioinformatics and wet-lab techniques, emphasizing interdisciplinary skills for microbiome research. Her work is supported by the National Institute of Allergy and Infectious Diseases and focuses on translating discoveries into clinical applications for global reproductive health improvement. Her laboratory operates within the Institute for Genome Sciences at the Health Sciences Facility III, where it combines multi-omics data integration, epidemiological modeling, and in vitro experimental systems to advance understanding of mucosal pathogenesis and develop microbiome-informed diagnostics.

Karolin Hijaziمشاهده پروفایل

استاد بالینی

• Microbial Diseases
• Antimicrobial Resistance
• Host-Microbe Interactions
• +۳ مورد دیگر

Dr. Karolin Hijazi is a Clinical Professor and Clinical Chair at the University of Aberdeen's Institute of Dentistry, within the School of Medicine, Medical Sciences and Nutrition. She graduated from the University of Siena (2004) and earned a PhD in Pathology from King's College London (2008). Her career includes postdoctoral research in HIV microbicides and clinical training in Oral Medicine. She has held roles as Senior Clinical Lecturer (2016) and Clinical Reader (2021) before her current appointment. She leads the Microbial Diseases Research Group and has secured over £1M in grants for collaborative projects. Her research focuses on host-microbe interactions, antimicrobial resistance, and oral-systemic health links. She serves on editorial boards (e.g., Journal of Global Antimicrobial Resistance) and evaluates grants for the European Commission and MRC. She is a Fellow of the Royal College of Surgeons of Edinburgh and an examiner for dental licensure in the UK and Europe. Her research interests span microbial pathogenesis, HIV prevention, and the role of oral microbiota in systemic diseases like cardiovascular conditions. She actively mentors students and postdocs, many of whom have won awards at national and international conferences. She also contributes to dental education research, exploring pedagogical strategies and assessment methods. Her work bridges clinical practice, basic science, and translational medicine, emphasizing global health challenges like antimicrobial resistance.

P. Scott Heftyمشاهده پروفایل

استاد

• Bacterial Pathogenesis
• Chlamydia Biology
• Infectious Disease
• +۳ مورد دیگر

P. Scott Hefty is a Professor and Chair of the Department of Molecular Biosciences at The University of Kansas, where he also serves as Director and Principal Investigator of the Center for Chemical Biology of Infectious Disease (CoBRE). His research focuses on molecular mechanisms of Chlamydia pathogenesis, addressing critical public health challenges posed by Chlamydia trachomatis and Chlamydia pneumoniae . His educational background includes a Ph.D. from the University of Oklahoma Health Sciences Center and postdoctoral training at the University of California, Berkeley. Dr. Hefty's research program investigates the transcriptional regulation of chlamydial developmental cycles, structural characterization of uncharacterized proteins (25-35% of the genome), and development of vaginal microbicides against C. trachomatis . His work tackles challenges like the absence of genetic manipulation systems and axenic cultivation limitations through biochemical, genomic, and structural biology approaches. No scientific awards were explicitly mentioned in the source text. As CoBRE Director, he oversees NIH-funded infrastructure supporting chemical biology research in infectious diseases. While the "Former Students" section confirms his mentoring activities, specific student names were not provided in the scraped content. He leads the Hefty Lab in Haworth Hall, utilizing interdisciplinary methods to study obligate intracellular pathogenesis and advance therapeutic strategies against high-burden infections.

• Drug Delivery Systems
• Nanoparticle Formulation
• Pharmaceutical Stability
• +۳ مورد دیگر

Dr. Richard Tettey Addo is a Professor of Pharmaceutical Sciences at Union University, where he teaches pharmaceutical calculations, Pharmaceutics, and sterile and non-sterile compounding to first and second year pharmacy students. He has previously served as an Assistant Professor of Pharmaceutical Sciences at Shenandoah University and as an Adjunct Professor of Pharmacogenomics at George Washington University School of Medicine. Dr. Addo's educational background includes: Ph.D. in Pharmaceutical Sciences from Mercer University College of Pharmacy and Health Sciences (2008) Bachelor of Science degree in Pharmacy (B. Pharm) from the University of Science and Technology, Ghana (2002) Dr. Addo's research focuses on innovative drug delivery systems, particularly in the areas of nanoparticle and microparticle formulation for protein pharmaceuticals. His work encompasses the stability of compounded formulations, dosage forms, and the development of delivery platforms for vaccines and cancer therapeutics. A significant aspect of his research involves creating controlled release biodegradable and targetable particle drug delivery systems prepared by one-step spray drying. His long-term research goal is to develop vaccine delivery strategies using micro- and nanoparticles that can stimulate the body's immune recognition and facilitate long-lasting immunity. Dr. Addo's scholarly output demonstrates a consistent focus on drug delivery systems, particularly for ocular applications, cancer therapeutics, and vaccine development. His work spans from fundamental formulation studies to preclinical evaluations, showing progression from basic research to more applied therapeutic development. The publications reveal expertise in albumin-based delivery systems, nanoparticle technology, and analytical method development for pharmaceutical products. Dr. Addo has received recognition for his scholarly work, including: Outstanding Poster and Presentation Award Winner at Graduate Research Association of Students of Pharmacy (GRASP), Florida A. and M. University, Tallahassee, Florida (2008) Dr. Addo has secured multiple research grants supporting his work in drug delivery and pharmaceutical formulation. These include funding from Union University's Pew Research Program for developing nano-sized particles containing anti-oxidants for age-related macular degeneration treatment, and grants from Main Street Pharmacy and the International Academy of Compounding Pharmacists for stability testing of compounded drugs. His grant portfolio reflects both academic and industry interest in his research on pharmaceutical formulation and drug delivery systems. While specific laboratory facilities aren't detailed in the available information, Dr. Addo's research program appears to focus on formulation development and characterization of drug delivery systems, particularly involving albumin-based micro- and nanoparticles. His work likely involves collaboration with other researchers in pharmaceutical sciences and potentially with clinicians for translational applications of his delivery systems.

• Peptide Self-Assembly
• Amyloid Peptides
• Amyloid-Inspired Materials
• +۳ مورد دیگر

Bradley L. Nilsson is a Professor of Chemistry and Director of the Materials Science Program at the University of Rochester's School of Arts & Sciences. He holds a PhD from the University of Wisconsin, Madison (2003). His research focuses on peptide self-assembly, particularly the study of amyloid peptides and their applications in functional materials,生物医药, and energy. Key projects include developing peptide-based hydrogels for tissue engineering, anti-HIV microbicides, and supramolecular materials derived from phenylalanine derivatives. His work also explores the noncovalent interactions driving self-assembly and their biomedical applications. Research interests span peptide self-assembly mechanisms, amyloid-inspired materials, and applications in drug delivery and nanotechnology. Notable contributions include the development of cyclic amphipathic peptides for siRNA delivery and the design of amyloid-mimetic hydrogels. His recent studies investigate quantum dot biomimetics for neuroinflammation research and the role of sequence patterns in peptide assembly. No scientific awards are explicitly listed in the provided text. His research has been supported by collaborative grants focusing on multi-component peptide nanofibrils and supramolecular materials. He leads the Materials Science Program, fostering interdisciplinary research in biomaterials and nanotechnology.

Elizabeth Brownمشاهده پروفایل

استاد پژوهشی

• HIV Prevention
• Infectious Disease Clinical Trials
• Biostatistics
• +۳ مورد دیگر

Elizabeth Brown is a Research Professor of Biostatistics at the University of Washington and a Professor at Fred Hutchinson Cancer Center, holding dual appointments in the Vaccine and Infectious Disease Division and Public Health Sciences Division. She is also a Member of the Translational Data Science Integrated Research Center (TDS IRC) at Fred Hutch. Her educational background includes: ScD in Biostatistics from Harvard University (2002) MS in Biometrics from University of Colorado (1998) BS in Mechanical Engineering from University of Virginia (1994) Dr. Brown specializes in designing and analyzing infectious disease clinical trials, with deep expertise in HIV prevention research. Her methodological work focuses on joint models for longitudinal and survival data, Bayesian statistics, and statistical methods for HIV/AIDS and cardiovascular research. She applies these approaches to critical public health challenges including COVID-19, HPV, and emerging pathogens. As Principal Investigator for the Microbicide Trials Network and Director of the Statistical and Data Sciences Unit for the Infectious Diseases Clinical Research Consortium, she leads major federally funded initiatives. Her current projects address SARS-CoV-2 treatments, HPV vaccine efficacy, and HIV prevention strategies through large-scale clinical trials. Dr. Brown's leadership has been featured in prominent outlets including Science Spotlight and Hutch News for her contributions to antiviral research, COVID-19 vaccine studies, and HIV prevention technologies like the dapivirine vaginal ring.

• Prevention of sexually transmitted infections
• Drug development of microbicides and live biotherapeutic products
• Fertility Choices
• +۳ مورد دیگر

Anke Hemmerling, MD, PhD, MPH is an Associate Adjunct Professor in the Department of Obstetrics, Gynecology and Reproductive Sciences at the University of California, San Francisco (UCSF), and serves as the Director of the Interdisciplinary MPH Program in the UC Berkeley School of Public Health. With a strong background in medicine, medical sciences, and public health, she bridges clinical practice, research, and education with a focus on global women's health. Dr. Hemmerling received her MD and PhD from Humboldt University in Berlin, Germany, and her MPH from the University of California, Berkeley. During her clinical training, she gained extensive experience working in health projects and hospitals in Latin America, which shaped her commitment to addressing global health disparities. Her research spans several interconnected areas of women's health, with a particular emphasis on preventing sexually transmitted infections, developing novel microbicides and live biotherapeutic products for HIV/STI prevention, understanding fertility choices, and promoting safe motherhood. She has made significant contributions to the field of vaginal microbiome research, particularly in developing LACTIN-V (Lactobacillus crispatus CTV-05) as a biotherapeutic for preventing bacterial vaginosis recurrence and HIV acquisition. Dr. Hemmerling has been actively involved in numerous clinical trials, including serving as protocol co-Chair for the NIH-sponsored multi-site phase 2B study for the prevention of bacterial vaginosis using LACTIN-V. Her work demonstrates a strong commitment to translating basic science discoveries into practical interventions that can improve women's health outcomes globally. She serves as a senior technical adviser for the Initiative for Multipurpose Prevention Technologies for Reproductive Health (IMPT) and participates in data safety monitoring boards for federally funded clinical studies. Additionally, she contributes to the Education Committee at the UCGHI Center of Expertise in Women's Health, Gender and Empowerment. Dr. Hemmerling is actively engaged in mentoring and teaching medical students, undergraduates, graduate students, and post-doctoral fellows across both UCSF and UC Berkeley. Her approach integrates clinical research with public health practice, emphasizing interdisciplinary collaboration and innovation in global education and capacity building.

• HIV prevention and treatment in women
• Vaginal microbicides
• Pre-exposure prophylaxis (PrEP)
• +۶ مورد دیگر

Marla J. Keller is a tenured Professor of Medicine and Obstetrics & Gynecology at Albert Einstein College of Medicine, holding the Jacob & Jeanne Barkey Chair in Medicine and serving as Executive Dean. She has held leadership roles including Interim Senior Associate Dean for Clinical and Translational Research and Director of the Block Institute for Clinical and Translational Research. Her clinical practice focuses on HIV, HSV, and inpatient infectious disease consultation. Education: B.A. in Psychology, Cornell University M.D., New York University School of Medicine Residency in Internal Medicine, Beth Israel Hospital Infectious Diseases Fellowship, Brigham & Women's Hospital Clinical Research Training Program, Mount Sinai School of Medicine Leadership Certification, Harvard University (2018) Research Interests: Dr. Keller's work centers on HIV prevention and treatment in women, vaginal microbicides, PrEP, and immune responses to SARS-CoV-2. Her NIH-funded studies include Phase I/II clinical trials of vaginal microbicides, cervical cancer screening in HIV+ women, and mucosal immunity analysis. She leads MACS/WIHS Cohort studies and contributed to NIH's 2020-2024 COVID-19 Treatment Guidelines. Publications & Awards: Over 80 peer-reviewed articles highlight her contributions to HIV prevention, vaginal microbiome research, and clinical trials. Awards include the 2023 Einstein Changemaker Award and recognition as a New York Super Doctor (2011-2015). Advocacy & Leadership: Co-chair of Montefiore's COVID-19 Taskforce, member of IDSA, HIVMA, and NIH panels. Her efforts bridge clinical care, research, and health system innovation.

Shendra Passicمشاهده پروفایل

پژوهشگر

• HIV Research
• Virology
• Immunology
• +۳ مورد دیگر

Shendra Passic is a Researcher and MS Research Instructor in the Department of Microbiology & Immunology at Drexel University College of Medicine. She holds leadership roles as Director of the Biosafety Level 3 (BSL-3) Facility, Manager of the Center for Molecular Virology and Neuroimmunology, and Director of the Human Cell Molecular Processing Center within the Institute for Molecular Medicine and Infectious Disease. She completed her MS in 1997 at Indiana University of Pennsylvania. Her research focuses on HIV-1 genetic variation, drug development, and microbicides, with emphasis on viral pathogenesis and cytokine profiling in infected patients. She oversees longitudinal cohort studies analyzing HIV genetic evolution and patient outcomes. Her work spans 15+ peer-reviewed publications (2002–2017) exploring HIV-1 tropism, neurocognitive impacts, coinfection effects, and antiviral mechanisms. She collaborates on projects involving cytokine analysis, drug development, and molecular virology. She manages key research facilities supporting HIV/AIDS research infrastructure. Key contributions include defining genetic signatures linked to disease progression, identifying neurocognitive correlates of Vpr protein variants, and investigating coinfection dynamics with hepatitis C. Her research bridges basic science and clinical applications in infectious disease.

Paul Edlefsenمشاهده پروفایل

دانشیار بالینی

• Statistical Genetics
• Bioinformatics
• HIV Vaccine Research
• +۵ مورد دیگر

Paul Edlefsen is a Principal Staff Scientist at Fred Hutchinson Cancer Research Center and holds the position of Clinical Associate Professor in the Department of Biostatistics at the University of Washington's School of Public Health. His work focuses on advancing infectious disease vaccine research through interdisciplinary approaches that integrate biology, biostatistics, and bioinformatics. He leads the Edlefsen Group at Fred Hutch, which collaborates with multiple labs and consortia on globally relevant problems in vaccine development. His educational background includes a PhD in Statistics (2009) and an AM in Statistics (2005) from Harvard University, and a BA in Computer Science (2000) from Wesleyan University. During his academic training, he also held a position as a Harvard College Fellow. Dr. Edlefsen's research program spans multiple critical areas of infectious disease research. His primary focus is on the genomics of pathogens, particularly HIV-1, with the goal of developing both prophylactic vaccines and cures. He has made significant contributions to sieve analysis methods, which examine pathogen sequence variation across clinical trial arms to identify evidence of vaccine-induced immunity. His methodological work encompasses three main areas: developments in Dempster-Shafer theory with Art Dempster, methods for inferring parameters of profile hidden Markov models applied to viral sequences, and sieve analysis methodology that accounts for subject-level heterogeneity. His publication record demonstrates consistent productivity in high-impact areas of HIV vaccine research, statistical methodology, and virology. Recent work shows a strong emphasis on understanding viral evolution in response to vaccine pressure, immune responses to co-infections (particularly SIV/HIV with other pathogens), and developing novel statistical methods for analyzing vaccine trial data. His research often bridges clinical applications with advanced statistical theory, reflecting his dual expertise in both domains. As a clinical trials statistician, Dr. Edlefsen works with multiple major HIV research networks including the HIV Vaccine Trials Network, HIV Prevention Trials Network, HIV Microbicide Trials Network, and the Gates Foundation's Coalition for AIDS Vaccine Discovery. His group at Fred Hutch maintains strong collaborative ties with researchers around the globe, contributing statistical and computational expertise to numerous vaccine development efforts. The Edlefsen Group operates as a small but diverse team of researchers who cross expertise barriers to communicate effectively about complex topics in statistics, bioinformatics, and infectious disease biology. The group actively participates in study design, grant writing, and reproducible data analysis, working closely with vaccine researchers throughout the scientific process. They welcome collaborations and maintain strong ties throughout the research community with the primary goal of advancing infectious disease vaccine research to improve public health worldwide.